JERSEY, Channel Islands, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Quotient Limited ("Quotient") (Nasdaq:QTNT), an established, commercial-stage diagnostics company, today announced the approval and launch of four new products to expand its reagent red cell product offering.
The four new products are:
-
ALBAcyte® Expanded Rh Negative Antibody Screen
-
ALBAcyte® Antibody Identification Panel (16-cell)
-
ALBAcyte® Antibody Screen (2-cell)
-
ALBAzyme® Papain Solution Kit
"These four new products expand our reagent red cell offering, including the addition of a number of novel products," said Jeremy Stackawitz, President of Quotient. "Quotient's product offering can now address all the needs of the vast majority of blood bank laboratories, truly making it a one-stop-shop for reagent red cells."
The ALBAcyte® Expanded Rh Negative Antibody Screen not only meets the needs of blood bank laboratories as a standard antibody screen, but can be of particular use with pregnant, Rh-negative women who have been treated with Rh Immunoglobulin. Its Rh-negative cells detect all the unexpected antibodies required of traditional screens. It is the only product of its kind on the market.
The ALBAcyte® Antibody Identification Panel (16-cell) is a full antibody identification panel that has six more complementary cells specifically requested by our customers to better aid antibody identification work ups.
The ALBAcyte® Antibody Screen (2-cell) is a robust antibody screen for those customers that prefer a 2-cell screen, or frequently test pediatric or other small-volume samples. Red cells incorporated in this product have been carefully selected to maximize homozygousity, thus optimizing the detection of antibodies.
The ALBAzyme® Papain Solution Kit is a kit combining both papain and enzyme control, which will pair with our existing papain-treated ALBAcyte® Antibody Identification Panel (10-cell), to better allow customers to treat and test auto-controls and patient samples.
The new products will be available for purchase and sampling later this month. Quotient will be launching these new products at 2014 AABB Annual Meeting in Philadelphia, PA (October 25-28).
About Quotient Limited
Quotient is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests, currently focused on blood grouping and serological disease screening. Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins, Switzerland.
CONTACT: Jeremy Stackawitz, President
Jeremy.Stackawitz@quotientbd.com
(215) 497-8820
